Innoviva (HVE) AI Stock Analysis

Innoviva

(Frankfurt:HVE)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

High cash generationConsistently strong operating and free cash flow indicate durable earnings quality and internal funding for R&D, acquisitions, or dividends. High cash conversion limits reliance on external financing and supports strategic flexibility over the next 2–6 months and beyond.

Negative Factors

Earnings volatilityLarge swings in margins suggest earnings are influenced by non‑recurring items or timing of investment gains, making forward cash flows less predictable. This undermines near‑term planning for capital allocation and could affect sustained payout or reinvestment policies.

Innoviva (HVE) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.52B
Dividend Yield: ―
Average Volume (3M): 212
Price to Earnings (P/E): 4.3
Beta (1Y): 0.14
Revenue Growth: 10.27%
EPS Growth: 718.25%
Country: Germany
Employees: 159
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Innoviva Business Overview & Revenue Model

Company Description

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which in...

Innoviva Risk Analysis

Innoviva disclosed 72 risk factors in its most recent earnings report. Innoviva reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Innoviva Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:HVE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GYRE	52Neutral	$482.98M	-23.78	-15.77%	―	16.83%	-494.61%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SVRA	51Neutral	$990.32M	-8.15	-90.28%	―	―	-12.40%
TRVI	51Neutral	$1.93B	-40.35	-23.59%	―	―	18.54%
MNKD	46Neutral	$1.13B	-26.16	78.60%	―	30.46%	-223.84%

* Healthcare Sector Average

Performance Comparison

DE:HVE and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:HVE	Innoviva	19.00	3.50	22.58%
MNKD	MannKind Corporation	3.65	-1.83	-33.39%
GYRE	Gyre Therapeutics Inc	4.73	-2.52	-34.76%
SVRA	Savara	4.73	0.60	14.53%
TRVI	Trevi Therapeutics	13.63	2.77	25.51%
AVLN	Avalyn Pharma Inc	25.60	-3.89	-13.19%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Innoviva AI Stock Analysis